Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the FDA.
The company’s 180-patient Promise trial is slated to study the safety and efficacy of the Eversense device in people with diabetes over 180 days.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics touts first U.S. trial implant of 180-day CGM appeared first on MassDevice.